1. P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECITABINE IN AML PATIENTS. (23rd June 2022) Authors: Geissler, K.; Koristek, Z.; Bernal del Castillo, T.; Novák, J.; Rodriguez Macias, G.; Metzelder, S. K.; Illes, A.; Nagy, A.; Mayer, J.; Arnan, M.; Keating, M.-M.; Krauter, J.; Lunghi, M.; Stefano Fracchiolla, N.; Platzbecker, U.; Santini, V.; Sano, Y.; Oganesian, A.; Keer, H.; Lübbert, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P582: FIRST RESULTS OF A PHASE II STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. (23rd June 2022) Authors: Zeidan, A. M.; Westermann, J.; Kovacsovics, T.; Assouline, S.; Schuh, A. C.; Kim, H.-J.; Rodriguez Macias, G.; Sanford, D.; Luskin, M. R.; Stein, E. M.; Malek, K.; Lyu, J.; Stegert, M.; Esteve, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 481 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗